Plex Pharmaceuticals, Inc., a subsidiary of Collidion Inc., is focused on improving the lives of patients diagnosed with complex degenerative diseases caused by protein misfolding. Plex's core competencies are in the discovery of drug-like small molecules by utilizing its core technologies, including functional fragment screening and X-ray crystallography to rationally design and synthesize New Chemical Entities (NCEs). Plex has several ongoing drug discovery programs to address unmet medical needs, including treatments for non-surgical cataracts, neurological disorders and infectious diseases. The team at Plex has amassed decades of drug discovery experience in numerous drug discovery programs which have successfully produced multiple clinical candidates, including one FDA approved drug.
